Merck said it plans to drop the price of its hepatitis C medication Zepatier by 60%, and Express Scripts said the drug will be a preferred product in the pharmacy benefit manager's list of covered medications in 2019. The development is expected to boost sales, and it may also provide marketing opportunities for, and access to, a new patient population.
Price cut for hepatitis C drug may boost access to new patient groups
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.